The Pathophysiology of Endothelin in Complications After Solid Organ Transplantation: A Potential Novel Therapeutic Role for Endothelin Receptor Antagonists

被引:42
作者
Raina, Amresh
Horn, Edward T. [2 ]
Benza, Raymond L. [1 ]
机构
[1] Temple Univ, Gerald McGinnis Cardiovasc Inst, Allegheny Gen Hosp, Coll Med,Sect Heart Failure Transplant & Pulm Hyp, 320 E N Ave, Pittsburgh, PA 15212 USA
[2] Allegheny Gen Hosp, Dept Pharm, Pittsburgh, PA 15212 USA
关键词
Endothelin; Solid organ transplantation; Complications; Graft survival; EPITHELIAL-MESENCHYMAL TRANSITION; PULMONARY ARTERIAL-HYPERTENSION; INDUCED RENAL VASOCONSTRICTION; CYCLOSPORINE-A; BLOOD-PRESSURE; ALLOGRAFT-REJECTION; INTERNATIONAL SOCIETY; LONG-TERM; BOSENTAN; HEART;
D O I
10.1097/TP.0b013e31825f0fbe
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Although short-term allograft survival after solid organ transplantation has improved during the past two decades, improvement in long-term graft survival has been less pronounced. Common complications after transplantation include chronic allograft rejection, nephrotoxicity from calcineurin inhibitors (CNIs), and systemic hypertension, which all impact posttransplantation morbidity and mortality. Endothelin (ET)-1, a potent endogenous vasoconstrictor, inducer of fibrosis, and vascular smooth muscle cell proliferation, may play a key role in both the development of CNI-induced nephrotoxicity and endothelial vasculopathy in chronic allograft rejection. ET-1 levels increase after isograft implantation, and ET-1 plays a key role in CNI-induced renal vasoconstriction, sodium retention, and hypertension. Preclinical studies have demonstrated that endothelin receptor antagonists (ERAs) can reduce or prevent CNI-induced hypertension after renal transplantation. In addition, ERAs can ameliorate CNI-induced renal vasoconstriction and improve proteinuria and preserve renal function in animal models of renal transplantation. ET-1 may also play a significant role in cardiac allograft vasculopathy, and in animal models, ERAs improve pulmonary function and ischemic-reperfusion injury in lung transplantation and hepatic function and structure in liver transplantation. Emerging pharmacokinetic data suggest that the selective ERA ambrisentan may be used safely in conjunction with the most commonly used immunosuppressive agents tacrolimus and mycophenolate, albeit with appropriate dose adjustment. The weight of available evidence pointing toward a potential beneficial role of ERAs in ameliorating common complications after solid organ transplantation must be balanced with potential toxicities of ERAs but suggests that a randomized clinical trial of ERAs in transplant patients is warranted.
引用
收藏
页码:885 / 893
页数:9
相关论文
共 91 条
[1]
Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans [J].
Antus, Balazs ;
Sebe, Attila ;
Fillinger, Janos ;
Jeney, Csaba ;
Horvath, Ildiko .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (11) :1324-1329
[2]
Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates [J].
Bartholomeusz, B ;
Hardy, KJ ;
Nelson, AS ;
Phillips, PA .
HYPERTENSION, 1996, 27 (06) :1341-1345
[3]
Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year [J].
Benigni, A ;
Bruzzi, I ;
Mister, M ;
Azzollini, N ;
Gaspari, F ;
Perico, N ;
Gotti, E ;
Bertani, T ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 1999, 55 (02) :674-685
[4]
Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy [J].
Bennett, WM ;
DeMattos, A ;
Meyer, MM ;
Andoh, T ;
Barry, JM .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1089-1100
[5]
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A [J].
Binet, I ;
Wallnöfer, A ;
Weber, C ;
Jones, R ;
Thiel, G .
KIDNEY INTERNATIONAL, 2000, 57 (01) :224-231
[6]
Black Henry R, 2007, J Clin Hypertens (Greenwich), V9, P760, DOI 10.1111/j.1524-6175.2007.07244.x
[7]
BLOOM ITM, 1993, SURGERY, V114, P480
[8]
New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone [J].
Bobadilla, Norma A. ;
Gamba, Gerardo .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 293 (01) :F2-F9
[9]
Regression of renal vascular fibrosis by endothelin receptor antagonism [J].
Boffa, JJ ;
Tharaux, PL ;
Dussaule, JC ;
Chatziantoniou, C .
HYPERTENSION, 2001, 37 (02) :490-496
[10]
Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist [J].
Braun, C ;
Conzelmann, T ;
Vetter, S ;
Schaub, M ;
Back, WE ;
Yard, B ;
Kirchengast, M ;
Tullius, SG ;
Schnülle, P ;
van der Woude, FJ ;
Rohmeiss, P .
TRANSPLANTATION, 1999, 68 (06) :739-746